Patents by Inventor Jonathan P. Ling

Jonathan P. Ling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR USING ALTERNATIVE SPLICING TO CONTROL SPECIFICITY OF GENE THERAPY
    Publication number: 20240108756
    Abstract: Disclosed herein are compositions and methods that can be used to express a nucleotide sequence in a specific cell type. The compositions can comprise nucleic acid constructs comprising a start codon; and an intron cassette. The intron cassette can comprise a cell specific exon sequence, a splice donor site, a branch site, and an acceptor site. The cell specific exon sequence is out of frame with the start codon and comprises one or more frameshift mutations. The compositions can be used to treat human diseases.
    Type: Application
    Filed: October 16, 2020
    Publication date: April 4, 2024
    Inventors: Jonathan P. Ling, Seth Blackshaw
  • TDP-43 IN DEGENERATIVE DISEASE
    Publication number: 20220283180
    Abstract: Chimeric proteins comprising an N-terminal domain derived from an N-terminal nucleotide binding domain of TDP-43 and a C-terminal domain derived from a splicing repressor are described. These proteins may be administered to a subject to treat or prevent disease manifesting TDP-43 proteinopathy such as inclusion body myocytosis, amyotrophic lateral sclerosis (ALS), or frontotemporal dementia (FTD).
    Type: Application
    Filed: March 2, 2021
    Publication date: September 8, 2022
    Inventors: Philip C. Wong, Jonathan P. Ling
  • ADENOVIRAL CHIMERIC TDP-43 PROTEINS
    Publication number: 20220275034
    Abstract: An adenovirus or adenoviral vector is described that includes a non-native nucleotide sequence capable of expressing a chimeric protein comprising an N-terminal nucleotide binding domain of transactivation response element DNA-binding protein (TDP-43), a C-terminal domain derived from a splicing repressor, and an autoregulatory element. Methods of using the adenovirus or adenoviral vector to treat degenerative diseases such as inclusion body myocytosis, amyotrophic lateral sclerosis, and frontotemporal dementia are also described.
    Type: Application
    Filed: November 4, 2019
    Publication date: September 1, 2022
    Inventors: Philip C. WONG, Aneesh DONDE, Jonathan P. LING, Liam CHEN, Mingkuan SUN
  • TDP-43 in degenerative disease
    Patent number: 10962551
    Abstract: Chimeric proteins comprising an N-terminal domain derived from an N-terminal nucleotide binding domain of TDP-43 and a C-terminal domain derived from a splicing repressor are described. These proteins may be administered to a subject to treat or prevent disease manifesting TDP-43 proteinopathy such as inclusion body myocytosis, amyotrophic lateral sclerosis (ALS), or frontotemporal dementia (FTD).
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: March 30, 2021
    Assignee: The Johns Hopkins University
    Inventors: Philip C. Wong, Jonathan P. Ling
  • TDP-43 IN DEGENERATIVE DISEASE
    Publication number: 20180372756
    Abstract: Chimeric proteins comprising an N-terminal domain derived from an N-terminal nucleotide binding domain of TDP-43 and a C-terminal domain derived from a splicing repressor are described. These proteins may be administered to a subject to treat or prevent disease manifesting TDP-43 proteinopathy such as inclusion body myocytosis, amyotrophic lateral sclerosis (ALS), or frontotemporal dementia (FTD).
    Type: Application
    Filed: June 17, 2016
    Publication date: December 27, 2018
    Inventors: Philip C. Wong, Jonathan P. Ling